Nonalcoholic Fatty Liver Disease in Children: Role of the Gut Microbiota by Li, Ding-You et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors




the world’s leading publisher of
Open Access books






Nonalcoholic Fatty Liver Disease in Children: Role of
the Gut Microbiota
Ding-You Li, Min Yang, Sitang Gong and
Shui Qing Ye
Additional information is available at the end of the chapter
http://dx.doi.org/10.5772/64799
Provisional chapter
Nonalcoholic Fatty Liver Disease in Children: Role of the
Gut Microbiota
Ding-You Li, Min Yang, Sitang Gong and
Shui Qing Ye
Additional information is available at the end of the chapter
Abstract
Nonalcoholic fatty liver disease (NAFLD) has emerged as the most common cause of
liver  disease  among  children  and  adolescents  in  industrialized  countries  due  to
increasing  prevalence  of  obesity.  It  is  generally  recognized  that  both  genetic  and
environmental  risk  factors  contribute  to  the  pathogenesis  of  NAFLD.  Convincing
evidences  have  shown  that  gut  microbiota  alteration  is  associated  with  NAFLD
pathogenesis both in patients and animal models. Bacterial overgrowth and increased
intestinal permeability are evident in NAFLD patients and lead to increased delivery
of gut-derived bacterial products, such as lipopolysaccharide and bacterial DNA, to
the liver through portal vein and then activation of toll-like receptors (TLRs), mainly
TLR4 and TLR9, and their downstream cytokines and chemokines, resulting in hepatic
inflammation. Currently, the role of gut microbiota in the pathogenesis of NAFLD is
still the focus of many active clinical/basic researches. Modulation of gut microbiota
with probiotics or prebiotics has been targeted as a preventive or therapeutic strategy
on  this  pathological  condition.  Their  beneficial  effects  on  the  NAFLD  have  been
demonstrated in animal models and limited human studies.
Keywords: nonalcoholic fatty liver disease (NAFLD), children, gut microbiota, probi-
otics, prebiotics
1. Introduction
A growing obesity epidemic over the past three decades has become a major public health
concern in developed as well as developing countries. According to the 2012 National Health
and Nutrition Examination Survey [1, 2], in the United States, 35.5% of men, 35.8% of women,
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and 16.9% of children (2–19 years old) were considered obese. The worldwide prevalence of
overweight and obesity increased from 28.8 to 36.9% in men, and from 29.8 to 38.0% in women
between 1980 and 2013 [3]. Specifically, the prevalence for children increased from 16.9 to
23.8% for boys and from 16.2 to 22.6% for girls in developed countries, and from 8.1 to 12.9%
for boys and from 8.4 to 13.4% for girls in developing countries as well [3].
Nonalcoholic fatty liver disease (NAFLD) has become the most common cause of liver disease
in children in industrialized countries due to increasing prevalence of obesity [4]. NAFLD is
defined as hepatic fat infiltration >5% of hepatocytes based on liver biopsy after excessive
alcohol intake, viral, autoimmune, or drug-induced liver disease have been excluded. NAFLD
is characterized by liver damage similar to that caused by alcohol but occurs in individuals
that do not consume toxic quantities of alcohol. NAFLD includes a spectrum of liver diseases
from simple fat infiltration (steatosis) through nonalcoholic steatohepatitis (NASH, steatosis
with liver inflammation) to hepatic fibrosis and even hepatocellular carcinoma. The prevalence
of NAFLD in the United States was 9.6% in normal weight children and 38% in obese ones
based on liver biopsy at autopsy after accidents [5]. In the United States, the highest rates of
pediatric NAFLD are in Hispanic and Asian children. In a study of 748 school children in
Taiwan, the rates of NAFLD were 3% in the normal weight, 25% in the overweight, and 76%
in the obese children determined by ultrasonography [6]. NAFLD in children is associated
with severe obesity and metabolic syndrome, which includes abdominal obesity, type-2
diabetes, dyslipidemia, and hypertension. This chapter briefly summarizes the current
understanding of the pathogenesis of NAFLD, role of gut microbiota, and potential new
treatment strategies.
2. NAFLD pathogenesis: current understanding
Although the pathogenesis of NAFLD is not completely understood, considerable progresses
have been made in recent years in explicating the mechanisms behind liver injury. As in other
complex diseases, both genetic and environmental factors contribute to NAFLD development
and progression. It is generally accepted that there is a genetic predisposition. In patients with
NAFLD, genomic studies have identified many single nucleotide polymorphisms (SNPs)
variants in genes controlling lipid metabolism, proinflammatory cytokines, fibrotic mediators,
and oxidative stress. The most important one is the patatin-like phospholipase domain-
containing 3 gene (PNPLA3) [7]. PNPLA3 rs738409 variant has been shown to confer suscept-
ibility to NAFLD in obese children in different ethnic groups [8]. Other reported susceptible
genes include glucokinase regulatory protein (GCKR), transmembrane 6 superfamily member
2 (TM6SF2), G-protein-coupled-receptor 120 (GPR120), farnesyl-diphosphate farnesyltrans-
ferase 1 (FDFT1), parvin beta (PARVB), sorting and assembly machinery component
(SAMM50), lipid phosphate phosphatase-related protein type 4 (LPPR4), solute carrier family
38 member 8 (SLC38A8), lymphocyte cytosolic protein-1 (LCP1), group-specific component
(GC), protein phosphatase 1 regulatory subunit 3b (PPP1R3B), lysophospholipase-like 1
(LYPLAL1), neurocan (NCAN), and polipoprotein C3 (APOC3) [9, 10]. To date, the strongest
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SNP variants associated with pediatric NAFLD are the rs738409 in the PNPLA3 gene, the
1260326 in the GCKR gene, and the rs58542926 in the TM6SF2 gene.
Day and James initially proposed a two-hit hypothesis to explain the pathogenesis of NAFLD
[11]. In individuals with genetic predisposition, the “first hit” results in liver fat accumulation
(steatosis) due to environmental factors (e.g., western diet and lack of physical activity),
obesity, insulin resistance, or metabolic syndrome. A subsequent “second hit”, such as free
fatty acids, adipokines/cytokines, oxidative stress (reactive oxygen species, lipid peroxidation),
gut microbiota-derived endotoxins, mitochondrial dysfunction, and stellate cell activation,
further amplify liver injury and NASH progression. A recent proposed multiple parallel hits
hypothesis suggested that gut-derived and adipose tissue-derived factors may play a central
role [12]. Both two-hit and multiple parallel hit hypotheses recognized that insulin resistance
plays a crucial role in NAFLD pathogenesis and other factors including genetic determinants,
nutritional factors, adipose tissue, and the immune system may be necessary for NAFLD
manifestation and progression [11–13]. A new lipotoxicity hypothesis proposes that insulin
resistance facilitates an excessive flow of free fatty acids to the liver, resulting in increased
production of lipotoxic intermediates and eventually NASH, through oxidative stress,
mitochondrial dysfunction, adiponectin, and other complex pathways [14, 15].
It has been well established that gut microbiota has been implicated in the development of
NAFLD through the gut-liver axis [16–18]. An alteration of gut microbiota composition leads
to bacterial overgrowth and increased intestinal permeability [19–21], resulting in transloca-
tion of gut micriobiota-derived products, such as lipopolysaccharide (LPS), bacterial DNA,
and peptidoglycan, which would activate liver cell surface receptors (TLR4 and 9); a cascade
of signal transductions is triggered and various cytokines and chemokines, such as TNF-α,
TGF-β, IL-6, IL-10, CCL2, CCL5, and CxCL8, are released, leading to hepatic inflammation and
fibrosis [22].
Evidences from both human and animal studies have supported important roles of gut
microbiota-derived endotoxins, especially LPS, and their downstream signal pathways in the
progression of NAFLD. Patients with NAFLD had increased serum endotoxin levels, with
marked increases noted in NASH and early stage fibrosis. The increase in endotoxin level is
related to IL-1α and TNF-α production [23–26]. In genetically obese fatty/fatty rats and obese/
obese mice, Yang et al. showed that LPS contributes to the development of steatohepatitis by
sensitizing TNF-α [27].
Toll-like receptors (TLRs) have been shown to play a crucial role in pathogenesis of NAFLD.
Activation of TLRs and the adaptor molecule, MyD88, results in a cascade of signal transduc-
tion leading to release of various cytokines (TNF-α, TGF-β, interleukin-6 (IL-6), and IL-10) and
chemokines (CCL2, CCL5, and CXCL8), which have been associated with NAFLD progression
and hepatic fibrosis, as demonstrated in both human and animal studies [28]. TLRs are a class
of pattern recognizing proteins that perceive bacterial and viral components. Gut microbiota
is a source of TLR ligands, which can stimulate production of proinflammatory cytokines in
the liver. TLRs are expressed on Kupffer cells, biliary epithelial cells, hepatocytes, hepatic
stellate cells, epithelial cells, and dendritic cells in the liver. Among 13 known TLRs, TLR2,
TLR4, and TLR9 have been implicated in NAFLD pathogenesis [17].
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TLR4 is mainly activated by LPS, a cell component of Gram-negative bacteria. Elevated
plasma and portal LPS levels are evident in human and animals with NAFLD [25, 29–32].
In methionine choline deficient diet(MCDD)-induced mouse model of NASH, liver injury
and inflammatory cytokine production increased after challenge with LPS [33]. Rivera et al.
further demonstrated histological change typical of steatohepatitis (extensive macrovesicu-
lar steatosis and necrosis), three-fold increase of portal blood endotoxin level, and en-
hanced TLR4 expression in wild-type mice fed with MCDD [31]. In a mouse model of
high-fat diet-induced NAFLD, TLR4 signaling is involved in free fatty-acid-induced NF-kB
activation in hepatocytes through release of free high-mobility group box1 (HMGB1),
which is a key molecule for the activation of the TLR4/MyD88-dependent pathway [34].
TLR4 mutant mice fed with fructose-enriched diet had significantly less hepatic steatosis
and lower TNFα levels in comparison to fructose-fed wild-type mice, indicating an impor-
tant role of LPS/TLR4 signaling in fructose-induced NAFLD [35]. Plasma LPS levels are al-
so markedly elevated in children and adults with NAFLD [25, 29, 30, 32]. Thus, gut
microbiota-derived LPS/TLR4 signaling pathway is crucial for the progression of NAFLD
in humans as well as animal models.
TLR9 is activated by bacterial DNA CpG motif and induces proinflammatory cytokine
production. In a mouse model of CDAA diet-induced NASH, Miura et al. showed hepatic
inflammation and fibrosis in wild-type mice, which was suppressed in mice deficient in TLR9
or MyD88, suggesting the critical role of the TLR9/MyD88 signaling pathway in the patho-
genesis of NASH [36].
Inflammasomes have been shown to be major contributors to inflammation and are upregu-
lated in mouse models of MCDD or high-fat-induced NASH and in livers of NASH patients.
Stimulation of TLR4 by LPS can further activate inflammasomes [37]. In genetic inflamma-
some-deficiency mice, an altered gut microbiota configuration is associated with abnormal
TLR4 and TLR9 agonist accumulation in the portal circulation, resulting in elevated hepatic
TNF-α expression and exacerbation of hepatic steatosis and inflammation [38].
TLR2 recognizes components from Gram-positive and Gram-negative bacteria, as well as
mycoplasma and yeast. In comparison to wild-type mice, TLR2-deficiency animals are
substantially protected from high-fat diet-induced adiposity, insulin resistance, hypercholes-
terolemia, and hepatic steatosis [39]. In contrast, increased hepatic inflammation and TNF-α
mRNA expression were observed in TLR2-deficiency mice fed with MCDD [33, 40]. The
conflicting results of the role of TLR2 signaling in those studies could be due to different animal
models used, different gut microbial ligands involved or compensation by other TLRs.
3. Modulation of gut microbiota: effects of prebiotics and probiotics on
NAFLD
Given the accumulating evidence of the critical role of gut microbiota in the pathogenesis of
NAFLD, microbiota manipulation has been targeted as a potentially therapeutic option for this
pathological condition. Possible strategies for altering gut microbiota include probiotics,
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prebiotics, synbiotics, antibiotics, dietary modification/supplementation, and microbiota
transplantation. So far, only probiotics have been tested for the treatment of NAFLD in animal
models and human subjects with promising effects.
Probiotics are live commensal microorganisms that have been shown to beneficially modulate
the host’s gut microbiota. In animal models of NAFLD, VSL#3 (a probiotic mixture containing
streptococcus, Bifidobacterium, and lactobacillus) improved hepatic inflammation and decreased
hepatic steatosis with reduction of serum alanine aminotransferase (ALT) levels. Those
changes were associated with decreased hepatic expression of TNF-mRNA and reduced
activity of Jun N-terminal kinase (JNK) [41–43]. In methionine choline deficient diet (MCDD)-
induced NASH rats treated with probiotic mixture containing 6 or 13 bacterial strains, which
were isolated from the healthy human stool samples, improved hepatic inflammation, likely
in part through modulation of TNF-α activity [44]. Furthermore, the treatment of apolipopro-
tein E-deficiency mice with dextran sulfate sodium (DSS) induced histopathological features
typical of steatohepatitis, which were prevented by 12-week VSL#3 administration, through
modulation of the expression of nuclear receptors, peroxisome proliferator-activated receptor-
γ, Farnesoid-X-receptors, and vitamin D receptor [45].
In human studies, Aller et al. reported that a 3-month treatment with Lactobacillus bulgaricus
and Streptococcus thermophilus improved liver aminotransferases in adult patients with NAFLD
[46]. Alisi et al. performed a double-blind and placebo-controlled RCT to assess the effect of
VSL#3 in 44 obese children with biopsy-proven NAFLD and demonstrated that VSL#3
supplement for 4 months significantly improved hepatic steatosis and BMI [47].
Prebiotics are nondigestible dietary fibers that stimulate the growth and activity of intestinal
bacteria. In genetically obese mice, supplementation with prebiotics (oligofructose, a mix of
fermentable dietary fibers) decreased plasma levels of LPS and cytokines (TNF-α, IL1b, IL1α,
IL6, and INFγ) and reduced gut permeability through a mechanism involving glucagon-like
peptide-2 [48]. Lactulose, as a prebiotic, can promote the growth of certain intestinal bacteria
such as Lactobacillus and Bifidobacterium. In a rat model of high-fat diet-induced steatohepatitis,
lactulose improved hepatic inflammatory activity and decreased serum endotoxin levels [49].
Human studies with prebiotics are very limited. In an earlier clinical pilot study in patients
with biopsy-proven NASH, dietary supplementation of oligofructose 16 g/day for 8 weeks
significantly decreased serum aminotransferases and insulin levels [50]. There have been no
randomized, controlled, double-blind, prospective clinical trials of prebiotics on NAFLD,
except a randomized controlled trial protocol, which will randomize adults with confirmed
NAFLD to either a 16 g/day prebiotic supplemented group or isocaloric placebo group for 24
weeks (n = 30/group) [51].
4. NAFLD in children
4.1. Gut microbiota and NAFLD in children
Given the important role of gut microbiota in obesity and metabolic syndrome [52, 53], it is
not surprising that ever-increasing literature in recent years suggested a potential role of gut
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microbiota in NAFLD pathogenesis. An observation by Spencer et al. provided the initial
evidence that gut microbiota and human fatty liver are closely linked [54]. In adult subjects
with choline-deficient diet-induced fatty liver, gut microbiota compositions were associated
with changes in liver fat in each subject during choline depletion. Subsequently, Mouzaki et
al. showed that patients with NASH had a lower percentage of Bacteroidetes compared to both
simple steatosis and healthy controls and higher fecal Clostridium coccoides compared to those
with simple steatosis [55]. There was an inverse and diet/BMI-independent association
between the presence of NASH and percentage of Bacteroidetes, suggesting a link between
gut microbiota and NAFLD severity. Raman et al. reported an over-representation of Lactoba‐
cillus species and selected members of phylum Firmicutes (Lachnospiraceae; genera, Dorea,
Robinsoniella, and Roseburia) in NAFLD patients [56]. A recent study identified Bacteroides
as independently associated with NASH and Ruminococcus with significant fibrosis and
further confirmed the association of NAFLD severity with gut dysbiosis [57].
In a pediatric cohort of 63 children, Zhu et al. determined the composition of gut bacterial
communities of obese children with NASH [58]. They found that Bacteroidetes were signifi-
cantly elevated (mainly Prevotella) in obese and NASH patients compared to lean healthy
children and that an increased abundance of ethanol-producing Escherichia in NASH children
was observed. Ethanol can promote gut permeability. A recent study by Michail et al. showed
that children with NAFLD had more abundant Gammaproteobacteria and Prevotella and
significantly higher levels of ethanol, with differential effects on short chain fatty acids [59].
Both studies demonstrated that the gut microbiota profile in pediatric NAFLD is different from
lean healthy children, with more ethanol-producing bacteria, suggesting that endogenous
alcohol production by intestinal microbiota may play a role in NAFLD pathogenesis. Engstler
et al. also showed that fasting ethanol levels were positively associated with measures of
insulin resistance and significantly higher in children with NAFLD than in controls [60].
Interestingly, with further animal experiments, they demonstrated that increased blood
ethanol levels in children with NAFLD may result from insulin-dependent impairments of
alcohol dehydrogenase activity in liver tissue rather than from an increased endogenous
ethanol synthesis [60]. Taken together, human studies demonstrated significant differences in
gut microbiota between normal subjects and patients with NAFLD. However, there were great
variations in microbiota compositions among these human studies, likely due to patient’s age,
fatty liver disease stages, study design, methods used, and observation endpoints.
4.2. Current management guidelines
All children with BMI ≥ 95th percentile or 85–94th percentile with risk factors (e.g., central
obesity, metabolic syndrome, and strong family history) are recommended to have liver
function test and hepatic ultrasonography [4, 61]. Since infants and children < 3 years old with
fatty liver are less likely to have NAFLD, tests should be performed to exclude genetic,
metabolic, syndromic, and systemic causes, such as fatty acid oxidation defects, lysosomal
storage diseases, and peroxisomal disorders. In older children and teenagers, metabolic,
infectious, toxic, and systemic causes should also be considered for differential diagnosis.
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Recommended common laboratory tests include viral hepatitis panel, α-1 antitrypsin pheno-
type, ceruloplasmin, antinuclear antibody, lipid profile, TSH, and celiac panel.
Ultrasonography is the only imaging technique used for NAFLD screening in children because
it is safe, noninvasive, widely available, relatively inexpensive, and can detect evidence of
portal hypertension. Liver biopsy is recommended to exclude other treatable disease, in cases
of clinically suspected advanced liver disease, before pharmacological/surgical treatment, and
as part of a structured intervention protocol or clinical research trial [4, 61].
Treatment options for children with NAFLD are limited by a small number of randomized
clinical trials and insufficient information on the natural history of the condition to assess risk-
benefit ratios [4, 62]. So far, weight loss, though hard to achieve, is still the cornerstone of
treatment regimen. Koot et al. demonstrated that a lifestyle intervention (physical exercise,
dietary change, and behavioral modification) of 6 months significantly improved hepatic
steatosis and serum aminotransferases in 144 children with NAFLD [63]. A long-term follow-
up study showed that the greatest decrease of NAFLD prevalence was observed in children
with the greatest overweight reduction [64]. Grønbæk et al. assessed the effect of a 10-week
“weight loss camp” (restricted caloric intake and moderate exercise for one hour daily) in 117
obese children and found that the children had an average weight loss of 7.1 ± 2.7 kg, with
significant improvements in hepatic steatosis, transaminases, and insulin sensitivity [65].
In children with poor adherence to lifestyle changes, pharmacological interventions and
dietary supplementations, including antioxidants (vitamin E), insulin sensitizers (metofor-
min), ursodeoxycholic acid (UDCA), omega-3 docosahexaenoic acid (DHA), and probiotics,
may be tried, but no randomized clinical trials have proved their effectiveness in children
with NAFLD.
5. Summary and future directions
The increase of pediatric NAFLD is attributed to the worldwide obesity epidemic. Current
evidences suggest that both genetic and environmental risk factors play a crucial role in the
pathogenesis of NAFLD in children and adolescents. Although human studies clearly showed
significant differences in gut microbiota between normal subjects and patients with NAFLD,
there were great variations in microbiota compositions among these studies [66]. Adult
patients have altered gut microbiota with an increase in the relative proportion of Bacteroidales
and Clostridiales, whereas in children with NAFLD, ethanol-producing bacteria are predom-
inant. Bacterial overgrowth and increased intestinal permeability are evident in NAFLD
patients and lead to increased delivery of gut-derived bacterial products (e.g., LPS and
bacterial DNA) to the liver through portal vein and then activation of toll-like receptors (TLRs),
mainly TLR4 and TLR9, and their downstream cytokines and chemokines, resulting in hepatic
inflammation [17].
Given the accumulating evidence of the critical role of gut-derived microbial factors in the
development and/or progression of NAFLD, modulation of gut microbiota with probiotics
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and/or prebiotics has been targeted as a therapeutic option. Their beneficial effects on NALFD
are promising based on studies in animal models and patients including children. However,
before probiotics and prebiotics become prime-time therapeutic modalities for NAFLD in
children, several issues need to be addressed. First, we still do not know whether all children
with NAFLD are truly associated with altered intestinal microbiota, and if so, which microbiota
is involved. Second, randomized clinical trials with appropriate powers are required to assess
benefits of tailored interventions with probiotics and/or prebiotics in children with NAFLD.
Finally, it is clinically important to know the best types of probiotics or prebiotics to be
prescribed in children with NAFLD. Nevertheless, probiotics and other integrated strategies
to modify intestinal microbiota are promising to become efficacious therapeutic modalities to
treat NALFD, with emerging evidence to demonstrate that prebiotics and probiotics modulate
the intestinal microbiota, improve epithelial barrier function, and reduce intestinal inflamma-
tion.
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